Lowering the annual cost of semaglutide by 18% or making the current cash price available to all patients would make it cost-effective.

Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an ...

Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular benefits for selected patients without diabetes who have established heart ...

Denmark: A study published in Cardiovascular Diabetology has found that patients with overweight or obesity who have prediabetes after a myocardial infarction face a substantially higher risk ...

In this study, semaglutide for the secondary prevention of cardiovascular disease was effective but meeting conventional ...

Him & Hers (NYSE:HIMS) shares are set to open 23% lower at about $18 after the telehealth company announced over the weekend ...

Researchers have found in a new real-world Pakistani cohort, once-weekly semaglutide achieved greater weight loss and HbA1c ...

Dr Reddy's Laboratories is set to launch a generic version of semaglutide in India on March 21. The company plans to offer both oral and injectable formats at competitive prices. This move aims to ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent ...

Find out more about how tirzepatide performed better than semaglutide in weight reduction in a 2026 network meta-analysis.

In this study, semaglutide for the secondary prevention of cardiovascular disease was effective but meeting conventional cost-effectiveness thresholds will require additional price reductions.